Brief: Klaria Signs Exclusive Development, License And Supply Agreements With Purdue Pharma (Canada)

Klaria Pharma Holding AB (publ)

22/01/2019 13:51

Jan 22 (Reuters) - Klaria Pharma Holding AB (publ)
 KLAR.ST :
    * KLARIA SIGNS EXCLUSIVE DEVELOPMENT, LICENSE AND SUPPLY
AGREEMENTS WITH PURDUE PHARMA (CANADA) FOR THE EMERGENCY
TREATMENT OF ANAPHYLACTIC REACTIONS (KL-01401)
    * PURDUE PHARMA - TOTAL VALUE OF ALL MILESTONES ACHIEVABLE
IS
$55.2 MILLION OF WHICH PAYMENTS AND NEAR-TERM MILESTONES ARE
$5.2 MILLION
    * PURDUE PHARMA - KLARIA WILL RECEIVE MID-TO-UPPER SINGLE
DIGIT
ROYALTIES ON NET SALES
    * PURDUE PHARMA - FURTHER TERMS OF AGREEMENTS GIVE KLARIA
EXCLUSIVE MANUFACTURING RIGHTS TO SUPPLY GLOBAL MARKET WITH
KL-01401
    * PURDUE PHARMA - KLARIA AB HAS ALSO ADDED EPINEPHRINE TO
ITS
LICENSE AGREEMENT WITH UPPSALAGRUPPEN MEDICAL AB
    * PURDUE PHARMA - IN LICENSE AGREEMENT, UPPSALAGRUPPEN WILL
RECEIVE A FOUR PERCENT ROYALTY ON KLARIA'S NET INCOME FROM SALES
OF KL-01401

Source text for Eikon:  ID:nCNWSQNbVa 
Further company coverage:  KLAR.ST 

 ((Reuters.Briefs@thomsonreuters.com;))